About PDS Biotechnology
PDS Biotechnology is a company with a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, cervical cancer, anal cancer, prostate cancer, and breast cancer, and other cancers.
PDS Biotechnology Patents
PDS Biotechnology has filed 24 patents.
Fatty acids, Immunology, Alkanoic acids, Immune system, Lipids
Fatty acids, Immunology, Alkanoic acids, Immune system, Lipids
Latest PDS Biotechnology News
Nov 28, 2023
Princeton, New Jersey, UNITED STATES PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced the appointment of Lars Boesgaard as Chief Financial Officer (CFO), effective as of December 4, 2023. Mr. Boesgaard succeeds Matthew Hill, who resigned as PDS Biotech’s CFO on November 21, 2023, effective December 1, 2023, to pursue other professional endeavors. “We are delighted to welcome Lars to the PDS Biotech team. He is an experienced CFO with an impressive track record of guiding biotech companies to create strategic growth. I look forward to his insights as well as his financial expertise and oversight as we continue to mature our business and advance our lead targeted cancer immunotherapy clinical candidates towards commercialization,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “Additionally, we would like to thank Matt for his contributions to PDS Biotech’s progress and wish him all the best in his new role.” Mr. Boesgaard has had a career spanning more than 25 years in healthcare and has deep capital markets and investor relations experience with global clinical and commercial-stage pharmaceutical and biotechnology companies. He has prepared and executed corporate transactions and built financial frameworks for rapidly growing organizations. Prior to joining PDS Biotech, Mr. Boesgaard served as CFO of AM-Pharma B.V. from September 2021 to August 2023. Mr. Boesgaard also served as CFO of Columbia Care from August 2018 to August 2021, where he completed key transactions including an IPO / reverse merger resulting in a $120 million capital infusion and raising $200 million in public equity and debt offerings. Mr. Boesgaard was also previously the Vice President, CFO of Roka Bioscience from November 2015 to July 2018 and held several other senior finance positions with publicly traded companies including Insulet Corporation, Alexion Pharmaceuticals and Novo Nordisk A/S. Mr. Boesgaard holds a Bachelor of Science in Business Administration from the Copenhagen Business School and a Master of Business Administration from the Richard Ivey School of Business, Western University, Ontario, Canada. “I’m excited to join PDS Biotech as the company advances its robust pipeline of groundbreaking targeted cancer immunotherapies,” said Mr. Boesgaard. “I look forward to working with the team to help drive PDS Biotech’s business strategy and financial growth.” About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS01ADC, and Infectimune® T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials and plan to advance into a Phase 3 clinical trial in combination with KEYTRUDA® for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in the first quarter 2024. Our Infectimune® based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. Forward Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; the Company’s ability to continue as a going concern; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation. KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA. Investor Contact:
PDS Biotechnology Frequently Asked Questions (FAQ)
Where is PDS Biotechnology's headquarters?
PDS Biotechnology's headquarters is located at 300 Connell Drive, Berkeley Heights.
What is PDS Biotechnology's latest funding round?
PDS Biotechnology's latest funding round is Reverse Merger.
How much did PDS Biotechnology raise?
PDS Biotechnology raised a total of $6.07M.
Who are the investors of PDS Biotechnology?
Investors of PDS Biotechnology include Edge Therapeutics, NetScientific, National Cancer Institute, Elevate Ventures, Asklepios Capital and 4 more.
Who are PDS Biotechnology's competitors?
Competitors of PDS Biotechnology include Array Biopharma, PaxVax, Celtaxsys, Vaccinogen, NewLink Genetics and 7 more.
Compare PDS Biotechnology to Competitors
Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.
SensiGen is a biotechnology company. They specialize creating tests to screen for diseases more efficiently and quickly. Their goal is to lower the overall costs of diagnosing serious diseases, usually ones where not many diagnostic tests exist.
Hawaii Biotech is a privately held biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. The company offers a range of products including vaccines for various diseases, small molecule drug candidates for the treatment of Anthrax and botulism, and high-quality proteins that elicit immune responses. These products are primarily targeted towards the healthcare and pharmaceutical industries. It was founded in 1982 and is based in Honolulu, Hawaii.
Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
Solixia is a biotechnology company dedicated to helping cancer patients through the use of nanoparticle technology.